CoChat

Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression

de Wit, Meike, Jimenez, Connie R, Carvalho, Beatriz, Belien, Jeroen A M, Delis-van Diemen, Pien M, Mongera, Sandra, Piersma, Sander R, Vikas, Maindad, Navani, Sanjay, Pontén, Fredrik, Meijer, Gerrit A, Fijneman, Remond J A · 2012 · Gut
Cited by 76

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background and objective: Early detection of colon adenomas at high risk of progression and early-stage colorectal cancer (CRC) is an effective approach to reduce CRC death rates. Current screening methods lack specificity as they detect many adenomas that will never progress to CRC. The authors aimed to identify cell surface protein biomarkers with extracellular domains that could be targeted for molecular imaging and discriminate low-risk adenomas and normal colon from high-risk adenomas and CRC. Design: Cell surface proteins of five CRC cell lines were biotinylated, isolated and analysed by in-depth proteomics using gel electrophoresis and nanoliquid chromatography coupled to tandem mass spectrometry. Differential expression in adenomas and CRCs was based on mRNA expression and verified by immunohistochemical staining of tissue microarrays. Results: In total, 2609 proteins were identified in the cell surface fractions. Of these, 44 proteins were selected as promising cell surface candidate biomarkers for adenoma-to-carcinoma progression based on the following criteria: protein identification in at least four out of five cell lines, a predicted (trans)membrane location and increased mRNA expression in CRCs compared to adenomas. Increased protein expression in high-risk adenomas and CRCs compared to low-risk adenomas was confirmed by immunohistochemistry for glucose transporter type 1 (gene symbol SLC2A1 ; p<0.00001) and prion protein (gene symbol PRNP ; p<0.005). Conclusion: This study revealed glucose transporter type 1, prion protein and 42 other cell surface candidate biomarkers for adenoma-to-carcinoma progression that could potentially serve as targets for emerging molecular imaging modalities like optical imaging, 19 F-MRI and positron emission tomography.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2011-300511

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 76

Metadata

Authors
de Wit, M., Jimenez, C. R., Carvalho, B., Belien, J. A. M., Delis-van Diemen, P. M., Mongera, S., Piersma, S. R., Vikas, M., Navani, S., Pontén, F., Meijer, G. A., & Fijneman, R. J. A.
Venue
Gut
Publisher
BMJ
Published
2011-09-02
Volume
61
Issue
6
Pages
855-864
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2100370963
Cited by
76
References
2
FWCI
3.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. https://app.cochat.ai/papers/10.1136/gutjnl-2011-300511
The paper
de Wit, M., Jimenez, C. R., Carvalho, B., Belien, J. A. M., Delis-van Diemen, P. M., Mongera, S., Piersma, S. R., Vikas, M., Navani, S., Pontén, F., Meijer, G. A., & Fijneman, R. J. A. (2012). Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut. https://doi.org/10.1136/gutjnl-2011-300511

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.